



ABN 53 075 582 740

22 November 2022

Section 708A Notice

This notice is given by Bionomics Limited ACN 075 582 740 (ASX:BNO) (**Bionomics**) under Section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (Corporations Act).

On 21 November 2022, Bionomics issued 115,384,680 fully paid ordinary shares (**Shares**) in accordance with the announcements made by Bionomics on 17 November 2022 and 22 November 2022.

Bionomics advises as follows:

- a) the Shares have been issued without disclosure under Part 6D.2 of the Corporations Act;
- b) as at the date of this notice, Bionomics has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to Bionomics; and
 - b. section 674 of the Corporations Act; and
- c) as at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act, other than as set out below.

Excluded information

The Company is proposing to issue up to 10 million unlisted options to acquire fully paid ordinary shares in the Company (**Options**) to the Company’s Executive Chair, Dr Errol De Souza. The terms of the Options (including any vesting and/or performance conditions) are still to be finalised and will be issued subject to shareholder approval under ASX Listing Rule 10.14. Once finalised, the Company will release the terms of the Options to ASX.

The Company is also in ongoing negotiations regarding the potential appointment of a new Chief Executive Officer (**CEO**). The terms of any agreement with the prospective CEO candidate are yet to be agreed. Should a new CEO be appointed, the Company will make an announcement to ASX in accordance with ASX Listing Rule 3.16.1 and release the material terms of any employment agreement in accordance with ASX Listing Rule 3.16.4.

Released on authority of the Board.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ms Suzanne Irwin
Company Secretary
CoSec@bionomics.com.au